FDA and state rules, for what you actually buy.

Must a pharmacy located in another state hold a license/registration from this state to ship prescriptions (including patient-specific 503A compounded preparations) to patients or practitioners here?

Under Miss. Code §73-21-106 as reenacted by HB 856 (2025), any pharmacy outside Mississippi that performs pharmacy services for Mississippi residents or businesses is a nonresident pharmacy and must be permitted by the Board of Pharmacy. The permit requirement also applies to any nonresident pharmacy that dispenses, distributes or ships prescription drugs directly to consumers in the state. Applicants must keep a valid home-state license and submit the most recent inspection report from their home-state regulator or a Board-approved inspecting entity. The pharmacist-in-charge must hold a Mississippi license as well as a home-state license, and cannot be PIC at any other Board-permitted location. The pharmacy also needs toll-free pharmacist access at least 6 days and 40 hours per week, with the number on labels. Pharmacies that compound also need a Board compounding certificate and must file an annual compounding statistical report (Board Regulations Art. XXXI).

HB 856 (effective on passage; Board says April 23, 2025) widened the nonresident definition to any pharmacy performing pharmacy services for Mississippi residents or businesses, including non-dispensing services. The statute text was read from the enrolled bill because the official code host (LexisNexis) and Justia/Casetext blocked access.

May a 503A (traditional) pharmacy dispense or distribute compounded preparations to a practitioner for office use (administration in the office, not patient-specific)? The federal position is that 503A requires patient-specific prescriptions; this is what the state pharmacy act and board rules allow.

Board Regulations Art. XXXI(1)(E) state: 'Pharmacies shall not offer compounded human drug products to practitioners or to other pharmacies for resale or dispensing,' and allow pharmacies to 'compound patient specific medications for office administration by a practitioner.' Art. XXXI(1)(B) and (D) allow compounding for an individual patient on a valid prescription, or in advance based on a history of prescriptions within an established pharmacist/patient/practitioner relationship. Art. XXXI(1)(G) treats distributing 'inordinate amounts' of compounded products without that relationship as manufacturing. Nonresident permit holders must certify that they will comply with Mississippi pharmacy laws and regulations (§73-21-106(2)(c)).

Possible tension: Art. XXXII(1)(A)(6) says a 503A pharmacy's sales of a 'prescription drug or device' to a practitioner for office use, up to 5% of its annual prescription sales, are not 'wholesale distribution' (so no distributor permit is needed). That definition does not mention compounding, and the compounding-specific Art. XXXI(1)(E) limits compounded human products to patient-specific medications. Confirm with the Board (compliance@mbp.ms.gov) before relying on the 5% language for compounded products. In the 2026 regulations the compounding article is Art. XXXI; the lead's 'Art. XXIV' is now Security of Controlled Substances.

Does the state require an FDA-registered 503B outsourcing facility located outside the state to hold a state license/registration (as an outsourcing facility, nonresident manufacturer, wholesaler or pharmacy) before shipping into the state?

Mississippi Board Regulations Art. VI(1)(F) and (2)(F) create a 'Sterile Product Outsourcing' permit for compounding and distributing sterile medications 'both in-state and out-of-state in accordance with FDA guidelines.' The facility must hold FDA outsourcing facility registration and follow cGMP. Its pharmacist-in-charge must certify full FDA and DEA compliance, and it may not share a location with a pharmacy permit. The Board's fee schedule lists 'Outsourcer (In-State and Out of State)' at $300, plus $50 for a controlled substance registration if needed. More broadly, Art. XXXII(2) requires every business distributing prescription drugs into Mississippi to register with the Board. Miss. Code §73-21-126, as amended in 2025, directs permits for in- and out-of-state entities 'owning or shipping into' Mississippi.

The Board's facility page lists 'Sterile Product Outsourcer' and 'Non-Resident Facility' applications, but their contents could not be extracted, so inspection-report specifics for nonresident outsourcers were not confirmed. Art. XXXII(3)(D) requires drug-facility permit applicants to submit an inspection from the last 3 years (the most recent FDA inspection has no time limit). A 503B that also dispenses patient-specific prescriptions into Mississippi may also need a nonresident pharmacy permit; check with the Board (licensing@mbp.ms.gov).

Has the state signed FDA's standard Memorandum of Understanding Addressing Certain Distributions of Compounded Human Drug Products (October 2020)? If not, FD&C Act §503A limits its 503A pharmacies' out-of-state distribution to 5% of total prescription orders (currently not enforced by FDA pending rulemaking).

Signing the standard MOU means the state board agrees to investigate complaints about compounded drugs its 503A pharmacies ship out of state and to identify and report to FDA pharmacies that distribute "inordinate amounts" interstate (more than 50% of their compounded prescriptions); in exchange, the statutory 5% out-of-state cap in FD&C Act §503A(b)(3)(B) does not apply to that state's pharmacies. FDA lists only Colorado, Kentucky and New Hampshire as signatories; Mississippi is not among them. For a non-signing state, FD&C Act §503A(b)(3)(B)(ii) caps a 503A pharmacy's out-of-state distribution of compounded drugs at 5% of its total prescription orders. FDA now considers the October 2020 standard MOU suspended (it does not expect signatory states to carry out MOU activities and will not sign new ones) and is not enforcing the 5% limit until a final rule and an updated MOU are published; FDA's rulemaking (RIN 0910-AI71) listed a proposed rule for 11/2026 in the Fall 2025 Unified Agenda.

The FDA list of signed MOUs (current as of 2023-01-23) is older than 2 years, but FDA stopped entering new agreements under the 2020 MOU in October 2022, so no state can have signed since. The FDA "Compounding Information for States" page (current as of 2026-08-28) still describes the MOU as awaiting rulemaking. Pending: FDA proposed rule on 503A distribution (RIN 0910-AI71, NPRM projected 11/2026); H.R. 5316 (introduced 2025-09-11, referred to House Energy & Commerce) would remove the MOU provision from §503A.

Besides DEA registration, does the state require practitioners to hold a separate state controlled substance registration, license or permit to prescribe, administer or dispense controlled substances (e.g. testosterone, Schedule III)? "Conditional" means a state registration is needed only in some settings, such as keeping controlled-substance stock in the office.

Miss. Code 41-29-125 lets the Board of Pharmacy, Board of Medical Licensure, Board of Nursing and others register persons who dispense controlled substances, with a separate registration per principal place of practice. Using that authority, Board of Medical Licensure rule (Part 2640, Chapter 1, Rule 1.3) requires every licensee who prescribes, administers or dispenses controlled substances to be registered with the DEA and with the Mississippi Prescription Monitoring Program, and 'adopts, in lieu of a separate registration with the Board, the registration with the U.S. Drug Enforcement Administration'. PAs are covered by the same in-lieu rule (Part 2615, Rule 1.5).

The statute also names the Mississippi Board of Nursing as a registering authority; whether it imposes its own registration on APRNs was not checked. The Board's dispensing-physician rules (Part 2640, Rule 1.9) apply to physicians who dispense.

Must a prescriber query the state Prescription Drug Monitoring Program before prescribing, and does the mandate cover Schedule III drugs such as testosterone? "Yes" means a mandate that reaches Schedule III; "conditional" means a mandate limited to certain drugs (e.g. opioids or benzodiazepines) or situations; "no" means no prescriber query mandate.

Board of Medical Licensure Rule 30-2640-1.3 requires every prescriber to register with the MPMP; pain management practices must review it at every encounter where a controlled substance is prescribed; all licensees must review it at every encounter where an opioid is prescribed for non-cancer pain; and other licensees must use it on initial contact with new patients and at least every 3 months for patients prescribed, administered or dispensed non-opioid controlled substances. The same rule states licensees issuing a prescription for Lomotil, Lyrica, testosterone, pseudoephedrine, or ADHD amphetamines for children under 16 are not required to use the MPMP in that instance; inpatient care is exempt but discharge prescriptions are not. Rule 1.10(H) requires a check for every benzodiazepine prescription. For APRNs, Board of Nursing Rule 30-2840-1.5 requires MPMP use for an initial controlled substance prescription and every opioid/benzodiazepine encounter, and likewise lets the APRN forgo it for testosterone.

Source older than 2 years - possibly stale (Rule 2640-1.3 last amended 10/29/2018; Rule 2840-1.5 amended 7/11/2024). Testosterone (C-III) is expressly carved out for both physicians/PAs and APRNs, though other Schedule III drugs are covered (new patient + every 3 months). Rules read on LII, not the Secretary of State's code site.

May physicians dispense prescription drugs (not just administer them) directly to patients from their practice? "Yes" means allowed under standard rules (labeling, records, and at most a simple notice to the board); "conditional" means a separate dispensing registration, permit or license, or quantity, day-supply or drug-category limits; "no" means prohibited except narrow exceptions.

A vendor summary reports that Mississippi physicians must register with the Mississippi State Board of Medical Licensure as dispensing physicians, complete at least 10 hours of Category 1 CME in pharmacology or medication dispensing beforehand, personally dispense (no delegation), and report dispensed controlled substances to the Mississippi PMP within 24 hours or the next business day. The board rule text was not reviewed.

Board rule not located by the research tools; confirm with the Mississippi State Board of Medical Licensure.

For a patient located in the state: must the prescriber hold this state's license (or a telehealth registration or special license), is an in-person exam required before prescribing (generally or for controlled substances), are there state limits on prescribing Schedule III drugs such as testosterone by telehealth, and is the state an Interstate Medical Licensure Compact member? "Yes" means a state license and the in-person standard of care apply (opioid-only or Schedule II-only limits are described but do not change the answer); "conditional" means extra state conditions such as a telehealth registration route, an in-person exam requirement, controlled-substance limits reaching Schedule III, or registration of telehealth businesses. Federal DEA rules apply on top.

A Mississippi-licensed practitioner may prescribe after an appropriate examination in person or through telemedicine instrumentation (Miss. Code 41-127-1). For controlled substances, a 'valid prescription' requires at least one in-person medical evaluation, except as authorized by Section 41-29-137.1 or for a practitioner engaged in telemedicine as authorized under state or federal law; a controlled-substance prescription based only on an online questionnaire is invalid (Miss. Code 41-29-137). How the telemedicine exception applies to testosterone should be confirmed with the Mississippi State Board of Medical Licensure. IMLC: member.

Board telemedicine rules were not read.

Who may administer botulinum toxin and dermal fillers (physicians, PAs, NPs, RNs, LPNs, estheticians, dentists), under what supervision (on-site vs available), and must a physician/NP/PA perform a prior good-faith exam?

The Mississippi Board of Nursing's position statement list (checked 2026-09-23) has no statement on cosmetic injectables, and the Board of Medical Licensure's Administrative Code (as amended February 2026) has no cosmetic-injection rule. The BML's IV guidance quotes Rule 1.11 of Part 2640: prescriptions may not be written outside a valid licensee-patient relationship, which includes an appropriate history and physical examination, a diagnosis and informed consent. How that applies to RN-administered neuromodulators and fillers has not been confirmed.

The BML declaratory opinion 'Practice of Medicine by Non-Licensees' (Jan. 2020) is a scanned PDF that could not be read as text. Check with the Board of Nursing and BML.

What does the state require for elective IV hydration/vitamin (incl. NAD+) therapy: who may start IVs, is a patient-specific order or good-faith exam required before a patient's first IV, are standing orders allowed, and are there rules for mobile IV services?

The Board of Nursing's IV Hydration position statement (April 2025, updated 2025-10-10) covers mobile units and wellness clinics: RNs may administer prescribed IV hydration, nutrient therapies and medications only with a valid individualized order and a completed history and physical by a physician, NP or PA; standing orders are not acceptable substitutes; LPNs may assist under RN/prescriber supervision; businesses must keep on-site policies and emergency procedures; and compounding is outside RN, APRN and LPN scope. The Board of Medical Licensure's 2023 guidance adds that IV fluids are legend drugs bought under a practitioner's DEA number, that a prescriber must establish the relationship, take a history, diagnose and prescribe for a specific patient, and that acting as a 'medical director' relying on standing orders is unprofessional conduct.

Does the state enforce the corporate practice of medicine doctrine (non-physicians may not own medical practices or employ physicians), and how does that affect med spa ownership?

Board Policy 3.02 (policies as revised December 2025) states the Board will not concern itself with the form or type of business arrangement a licensee enters into, provided the physician is Board-licensed, treatment decisions and billing are left to the physician's sole discretion free of influence, and there are no referral inducements or anti-kickback violations. Permit Health nonetheless rates Mississippi 'Mixed/Unclear', citing optometry-era cases (Sears Roebuck v. State Bd. of Optometry, 1952; Busch Jewelry, 1953) alongside Policy 3.02.

Policy compilation dated 'as last revised December 2025' (recorded as 2025-12-01).

Who may perform laser/IPL/RF aesthetic procedures (laser hair removal, resurfacing): physicians only, delegated to RNs/PAs, or licensed electrologists/estheticians/laser technicians with state certification?

Board of Medical Licensure Rule 3.1 (Part 2635, Chapter 3) says use of laser, pulsed light or similar devices, for invasive or cosmetic procedures, is the practice of medicine and is limited to physicians and those directly supervised by physicians, such that a physician is on the premises and would be directly involved in treatment if required. Dentists using lasers solely for dentistry are exempt. The rule does not limit which staff may be supervised, but requires on-site physician presence.

Code compilation 'as last amended February 2026' (recorded as 2026-02-01); Rule 3.1 itself last amended 2008.

Does the state license clinical laboratories itself, beyond federal CLIA certification, including out-of-state labs that test specimens from the state?

Most states rely on federal CLIA certification alone. The states confirmed in this research as issuing their own lab licenses are California, New York, Pennsylvania, Maryland and Rhode Island (which also reach out-of-state labs testing specimens from their residents), plus Nevada, Washington, Massachusetts, New Jersey and New Hampshire (labs located in the state). Mississippi was not among them, but this research did not confirm its statutes. Mississippi's CLIA state agency is Mississippi State Dept. of Health, Licensure and Certification/CLIA (CLIA-MSDH@msdh.ms.gov, 601-364-1115); it can confirm whether any state license or permit applies, including to out-of-state labs.

Absence of a state license was not verified against the state's statutes or rules.

May consumers order their own lab tests without a practitioner order (direct access testing)? A practitioner-ordered panel is always fine; this matters for take-home and consumer test kits.

ADLM (formerly AACC) reported in 2019 that 37 states and DC let consumers order some or all tests directly, but it did not publish the state list, and this research did not confirm Mississippi's rule. Mississippi's lab regulator (CLIA state agency) is Mississippi State Dept. of Health, Licensure and Certification/CLIA (CLIA-MSDH@msdh.ms.gov, 601-364-1115). The question matters for take-home and consumer test kits, not for panels a clinician orders.

The ADLM figure dates from 2019 (older than 2 years).

Has the state enacted a law or rule specifically about stem cell, exosome or regenerative-medicine therapies (notice/disclosure duties, permission for certain non-FDA-approved uses, or Right to Try extensions covering them)?

SB 2830 (approved June 25, 2020) amended the Right to Try Act (Miss. Code §41-131-1) to include 'adult autologous mesenchymal stem cell' treatments. Eligible patients have a debilitating disability, traumatic injury, terminal illness or life-threatening illness that has not responded to approved products. The treatment must have completed Phase 1 of a clinical trial and remain under investigation, among other listed criteria (an FDA/NIH-approved protocol, IRB approval, or a completed safety study). Written informed consent is required. Federal FDA rules still apply regardless of state law: stem cell, birth-tissue and exosome products are regulated by FDA, and a state law cannot make an unapproved biologic FDA-approved.

Autologous cells only; the law does not cover allogeneic birth-tissue products or exosomes. Statute text accessed via FindLaw (current as of Jan 1, 2025).

Does the state have cosmetic or sunscreen requirements beyond federal MoCRA, such as ingredient bans (PFAS, formaldehyde, phthalates), ingredient reporting, sunscreen-ingredient bans, or bans on selling animal-tested cosmetics?

Mississippi does not appear on 2026 compilations of state PFAS-in-cosmetics laws, on the list of states banning animal-tested cosmetics, or among the jurisdictions with sunscreen-ingredient bans. Federal MoCRA and FDA rules on cosmetics and OTC sunscreens still apply. Other state laws that touch cosmetics generally, such as state food-drug-cosmetic acts or consumer-protection laws, were not surveyed.

The animal-testing list is Wikipedia's 'as of 2023' compilation (older than 2 years); effective dates were not confirmed.